INKT News and Press, MiNK Therapeutics Inc.

First patients treated with agenT-797 were alive and afebrile at endpoint Day 28 with improved oxygenation, infection control and removal from ventilator and vasopressor support Analysis of blood and lung fluid showed signals of infection control and biological changes associated with immune r...

NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics , Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune disorders, today announced that it will report financial results for t...

NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced that its Annual Shareholders Meeting will begin at ...

First patient dosed marks rapid transition from trial activation to active treatment in patients with acute lung injury from all cause pneumonia meeting Global ARDS criteria Landmark advances a first-in-class immune therapy for critical illness where there are no approved mortality-reducing th...

agenT-797 demonstrates pathogen suppression, lung immune restoration and tissue repair activation, supporting Ongoing Phase 2 trial Sequential immunotherapy with agenT-797 and N-803, an FDA-approved IL-15 superagonist, Anktiva® may provide impactful clinical combination targeting Coccidioid...

2026-05-15 16:51:28 ET More on MiNK Therapeutics MiNK Therapeutics, Inc. (INKT) Q1 2026 Earnings Call Transcript MiNK Therapeutics, Inc. (INKT) Q4 2025 Earnings Call Transcript MiNK outlines initial ARDS Phase II data in H2 2026 while extending runway through 2026 ...

2026-05-15 16:50:43 ET MiNK Therapeutics, Inc. (INKT) Q1 2026 Earnings Call May 15, 2026 8:30 AM EDT Company Participants Stefanie Perna-Nacar Jennifer Buell - Co-Founder, President, CEO & Director Terese Hammond - Head of Inflammatory & Pulmonary Diseases ...

2026-05-15 11:41:01 ET Image source: The Motley Fool. Tuesday, March 31, 2026 at 5:30 a.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading

2026-05-15 11:38:46 ET Image source: The Motley Fool. Friday, May 15, 2026 at 8:30 a.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading

2026-05-15 07:43:30 ET More on MiNK Therapeutics MiNK Therapeutics, Inc. (INKT) Q4 2025 Earnings Call Transcript MiNK outlines initial ARDS Phase II data in H2 2026 while extending runway through 2026 MiNK Therapeutics rockets 60% after collaboration with C-Further f...